Journal articleMol Cancer2026
Therapeutic reprogramming of tumour-associated macrophages in pancreatic cancer using a cytotoxic CCR2-targeted nanotheranostic.
- Journal
- Mol Cancer
- Published
- 7 February 2026
- Citations
- 5
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Grants 7
- Core A: Administrative Core P50CA272213↗
- Targeting tumor innate immune signaling in pancreatic cancer R01CA219697↗
- Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy R01CA235672↗
- Re-wiring PDAC Tumor Immunity Through Dendritic Cells R01CA262506↗
- Stomal Senescence Regulator of Tumor Immunity and Progression R01CA286615↗
- IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA R37CA219697↗
- The Impact of Metastatic Site On Dendritic Cell-Driven Tumor Immunity U01CA284086↗